HAP Trading’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-12,000
Closed -$14.8K 839
2024
Q4
$14.8K Buy
12,000
+1,100
+10% +$23.3K ﹤0.01% 595
2024
Q3
$1.12K Sell
10,900
-600
-5% -$10.9K ﹤0.01% 660
2024
Q2
$4.05K Sell
11,500
-134,800
-92% -$2.37M ﹤0.01% 610
2024
Q1
$16.3K Buy
146,300
+106,800
+270% +$1.57M ﹤0.01% 549
2023
Q4
$12.3K Sell
39,500
-1,100
-3% -$14.7K ﹤0.01% 673
2023
Q3
$19.8K Buy
+40,600
New +$1.17M ﹤0.01% 680
2023
Q1
Sell
-22,500
Closed -$79K 1530
2022
Q4
$79K Buy
22,500
+700
+3% +$52.7K 0.01% 626
2022
Q3
$54K Buy
21,800
+3,800
+21% +$296K ﹤0.01% 963
2022
Q2
$46K Sell
18,000
-2,800
-13% -$211K ﹤0.01% 1084
2022
Q1
$110K Sell
20,800
-10,300
-33% -$759K ﹤0.01% 1015
2021
Q4
$111K Buy
31,100
+7,200
+30% +$723K ﹤0.01% 1205
2021
Q3
$216K Buy
23,900
+700
+3% +$106K 0.01% 1006
2021
Q2
$1.15M Buy
23,200
+13,900
+149% +$2.7M 0.04% 418
2021
Q1
$216K Sell
9,300
-7,200
-44% -$1.14M 0.01% 742
2020
Q4
$1.02M Sell
16,500
-12,100
-42% -$1.66M 0.03% 418
2020
Q3
$711K Buy
+28,600
New +$2.29M 0.04% 329
2020
Q1
Sell
-21,700
Closed -$131K 1419
2019
Q4
$131K Sell
21,700
-6,700
-24% -$541K 0.01% 519
2019
Q3
$236K Buy
+28,400
New +$2.27M 0.02% 455
2018
Q4
Sell
-31,000
Closed -$567K 1252
2018
Q3
$567K Buy
31,000
+15,000
+94% +$597K 0.04% 285
2018
Q2
$36K Buy
+16,000
New +$445K ﹤0.01% 733

Other funds holding NVCR

HAP Trading's NVCR Position: Q2 2024 in Review

HAP Trading sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 82,757 shares — an estimated $1.46M sold.

HAP Trading first reported a position in NVCR in Q1 2022 and held it in 5 quarters. The position peaked at $3.35M in Q3 2022. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • HAP Trading reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • HAP Trading sold 82,757 NovoCure shares in Q2 2024, an estimated $1.46M.
  • HAP Trading first reported a position in NovoCure in Q1 2022 and held it in 5 quarters.
  • HAP Trading's NovoCure position peaked at $3.35M in Q3 2022.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.